Stocks analysis

ABT vs AIG Stock Comparison

Scores Breakdown

Metric ABT AIG
📈 Growth 22/30 23/30
💰 Profitability 17/20 12/20
🏦 Financial Health 15/20 15/20
💵 Valuation 12/20 10/20
⚠️ Risk (lower is better) 4/10 6/10
Overall Score 72/100 64/100

Side-by-Side Summaries

ABT Analysis AIG Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (1.3–1.5) and modest long-term debt ($14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

  • Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
  • Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues stayed broadly flat in the $6.4B–$7.2B range, peaking at about $7.18B in 2024 Q4 and easing to around $6.65B by 2026 Q1. Net income progressed from a sizable quarterly loss in 2024 Q3 (~-$3.88B) to positive earnings from 2024 Q4 onward, with a peak near $1.14B in 2025 Q2, then moderating to roughly $0.52B–$0.76B across 2025 Q3–2026 Q1. This reflects meaningful earnings leverage despite a relatively flat revenue base, with a notable mid-2025 uplift followed by stabilization.

💰 Margins & Cash Flow

Operating margins swung from the mid-teens to the low- to mid-20s in 2025 Q2 (peak around 22%), indicating strong operating leverage when volumes align with cost structure. Across quarters, the average margin sits in the low-teens, roughly around 12%. Operating cash flow was positive in most periods, signaling solid cash generation from core activities, while investing cash flow fluctuated and financing cash flow was typically negative, reflecting ongoing debt management and capital activity.

🛡️ Balance Sheet & Liquidity

Assets run roughly $160–$166B with liabilities near $120–$125B and equity around $40–$41B, suggesting a solid asset base and meaningful equity cushion. The structure implies resilience supported by recurring operating cash flow, albeit with ongoing financing activity.

⚠️ Key Drivers & Risks

  • Drivers: Steady core insurance volumes and favorable investment environment supporting earnings uplift.
  • Risks: Earnings volatility from reserve development and sensitivity to macro/regulatory shifts that can affect margins.